NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE
UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION
OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF
ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 24 June 2024

Reference is made to the stock exchange announcement by Observe Medical ASA
("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today, regarding
the placement of a private placement (the "Private Placement"), where it was
also stated that the board of directors intends to carry out a subsequent
offering (the "Subsequent Offering") directed at shareholders in the Company as
of 24 June 2024 (as registered in the VPS on 26 June 2024) who (i) were not
allocated shares in the Private Placement and (ii) are not domiciled in a
jurisdiction where such offering would be unlawful, or, would, in jurisdictions
other than Norway, require any prospectus, filing, registration or similar
action. Completion of the Subsequent Offering will be subject to (i) approval
from the Company's extraordinary general meeting, (ii) completion of the Private
Placement and (iii) the publication of a prospectus by the Company that is
approved by the Financial Supervisory Authority of Norway.

Date on which the terms and conditions of the repair issue were announced: 24
June 2024

Last day including right: 24 June 2024

Ex-date: 25 June 2024

Record date: 26 June 2024

Date of approval: 17 July 2024

Maximum number of new shares: 32,500,000

Subscription price: NOK 0.40

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

This information is published in accordance with the requirements of the
Continuing Obligations.